Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

Loxo Oncology Inc.

Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. *


Period Start 2017-07-31 existent
  Group Eli Lilly (Group)
Products Industry larotrectinib (LOXO-101)
  Industry 2 BAY 2731954 (LOXO-195)
Person Person Bilenker, Josh (Loxo Oncology 201811 CEO)
  Street 281 Tresser Blvd.
9th Floor
  City 06901 Stamford, CT
  Tel +1-203-653-3880
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: Loxo Oncology, Inc.. (11/14/17). "Press Release: Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195". Stamford, CT.
Record changed: 2021-01-31


Picture [iito] Plain Stupid Simple 650x80px

More documents for Eli Lilly (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Bionnale 2021 Digital Event 650x80px

» top